Zentalis Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $300.00K.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $602.00K.
- Zentalis Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2023-12-31 | $602.00K 10-K · filed 2026-03-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2021-12-31 | $44.61M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $300.00K derived: sum of 2 quarters · filed 2023-03-01 | $300.00K derived: sum of 3 quarters · filed 2023-03-01 | $300.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $0.00 10-Q · filed 2020-08-13 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | -$1.26M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | -$1.26M derived: sum of 3 quarters · filed 2022-02-24 | $43.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.26M derived: sum of 2 quarters · filed 2022-02-24 | $43.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.41M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $43.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.41M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $2.67M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $1.37M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |